| Website | glycomimetics.com |
| Category | BioTech |
| Phone | 240-243-1201 |
| webmaster@glycomi... | |
| Employees | |
| Founded | 2003 |
| TOTAL | $38M |
| FUNDING TOTAL | $38M |
| Series C, 12/09 New Enterprise Associates Novartis Venture Fund Anthem Capital Management Alliance Technology Ventures Genzyme Ventures | $38M |
GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.
